REGENXBIO Inc.
RGNX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $29,733 | $21,359 | $89,012 | $21,214 |
| % Growth | 39.2% | -76% | 319.6% | – |
| Cost of Goods Sold | $61,826 | $9,114 | $3,436 | $6,318 |
| Gross Profit | -$32,093 | $12,245 | $85,576 | $14,896 |
| % Margin | -107.9% | 57.3% | 96.1% | 70.2% |
| R&D Expenses | $56,101 | $55,595 | $53,087 | $50,380 |
| G&A Expenses | $20,253 | $19,883 | $20,347 | $20,051 |
| SG&A Expenses | $20,253 | $19,883 | $20,347 | $20,051 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$56,036 | $45 | $15 | -$4,167 |
| Operating Expenses | $20,318 | $75,523 | $73,449 | $66,264 |
| Operating Income | -$52,411 | -$63,278 | $12,127 | -$51,368 |
| % Margin | -176.3% | -296.3% | 13.6% | -242.1% |
| Other Income/Exp. Net | -$9,530 | -$7,593 | -$6,044 | $182 |
| Pre-Tax Income | -$61,941 | -$70,871 | $6,083 | -$51,186 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$61,941 | -$70,871 | $6,083 | -$51,186 |
| % Margin | -208.3% | -331.8% | 6.8% | -241.3% |
| EPS | -1.2 | -1.38 | 0.12 | -1.01 |
| % Growth | 13% | -1,250% | 111.9% | – |
| EPS Diluted | -1.2 | -1.38 | 0.12 | -1.01 |
| Weighted Avg Shares Out | 51,689 | 51,483 | 51,362 | 50,871 |
| Weighted Avg Shares Out Dil | 51,689 | 51,483 | 51,434 | 50,871 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $3,400 | $0 | $83 |
| Interest Expense | $13,169 | $10,993 | $8,570 | $9,417 |
| Depreciation & Amortization | $3,886 | $3,905 | $3,955 | $4,023 |
| EBITDA | -$44,886 | -$55,973 | $18,608 | -$37,746 |
| % Margin | -151% | -262.1% | 20.9% | -177.9% |